IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with a 14.7-month increase in median overall survival compared to chemotherapy alone. The findings support the ongoing Phase 3 OVATION 3 trial, aiming to confirm these benefits and further explore the immunological effects. IMNN-001 uses a DNA-based therapy to locally deliver IL-12, transforming the tumor environment to boost immune response with minimal side effects.
IMUNON's new translational data on IMNN-001 in advanced ovarian cancer provides context for readers following health innovations. For readers following the health sector, here is Pluang's market snapshot as of Nov 06, 2026 19:41 WIB: out of 150 priced US health stocks, 52 rose and 90 fell. Notable movers include HALO at USD 117.01 down 4.84%, SNN at USD 30.70 down 4.09%, and TXG at USD 55.80 down 3.89% with 88% of orders selling.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
